Quote | Super Quote
69155 HS#ALIBARP2512D (R BEAR)
RT Nominal up0.111 +0.013 (+13.265%)

11/01/2022 17:50

CSPC Pharma (01093) gets drug registration approval

[ET Net News Agency, 11 January 2022] CSPC Pharmaceutical Group Limited (01093) said
the "Mitoxantrone Hydrochloride Liposome Injection (10ml:10mg)" developed by CSPC Zhongnuo
Pharmaceutical (Shijiazhuang) Co., Ltd, a subsidiary of the company, has obtained drug
registration approval granted by the National Medical Products Administration of the
People's Republic of China for the treatment of relapsed/refractory peripheral T-cell
lymphoma (PTCL).
It is an anti-tumour nanodrug independently developed by the group and is also the first
mitoxantrone nanodrug launched worldwide, representing a breakthrough in China as there
have been no innovative nanodrugs launched for years. (RC)

Remark: Real time quote last updated: 19/04/2024 11:53
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.